Curasight (CURAS.CO)

Executive Summary

Curasight is a Danish clinical-stage radiopharmaceutical company developing a novel theranostics platform targeting the urokinase-type plasminogen activator receptor (uPAR) for improved cancer diagnosis and treatment. Its lead candidates include uTRACE®, a clinically validated uPAR-PET diagnostic imaging agent, and uTREAT®, a first-in-class uPAR-targeted radioligand therapy (RLT). The platform aims to precisely target aggressive solid tumors while minimizing damage to healthy tissue, addressing a significant unmet need in oncology. Founded in 2017 and listed on the Copenhagen Stock Exchange (CURAS.CO), the company has advanced uTRACE through clinical validation and is now initiating Phase 1/2a trials for uTREAT. With a strong intellectual property position and growing interest in theranostics, Curasight is positioned to capitalize on the expanding radiopharmaceutical market. Recent progress includes ongoing patient enrollment in the uTREAT Phase 1/2a trial for multiple solid tumor types, with initial safety and efficacy data expected in late 2026. The uTRACE platform continues to generate clinical data supporting its use in various cancers, potentially broadening its diagnostic utility. While still in early clinical stages, Curasight's differentiated uPAR-targeting approach and dual diagnostic-therapeutic capabilities provide a unique value proposition. The company is also exploring strategic partnerships for uTRACE commercialization and further development of uTREAT. Investors should monitor upcoming data readouts and partnership announcements as key value inflection points.

Upcoming Catalysts (preview)

• H2 2026Initial Phase 1/2a data for uTREAT in solid tumors15% success
• Q1 2027Expansion of uTRACE into new oncology indications (e.g., prostate, breast)70% success
• H1 2027Strategic partnership or licensing deal for uTRACE commercialization50% success